GURUFOCUS.COM » STOCK LIST » USA » NAS » Intercept Pharmaceuticals Inc (NAS:ICPT) » Definitions » E10
Switch to:

Intercept Pharmaceuticals (NAS:ICPT) E10

: $-10.63 (As of Mar. 2023)
View and export this data going back to 2012. Start your Free Trial

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Intercept Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2023 was $-0.770. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-10.63 for the trailing ten years ended in Mar. 2023.

As of today (2023-05-29), Intercept Pharmaceuticals's current stock price is $10.26. Intercept Pharmaceuticals's E10 for the quarter that ended in Mar. 2023 was $-10.63. Intercept Pharmaceuticals's Shiller PE Ratio of today is .


Intercept Pharmaceuticals E10 Historical Data

The historical data trend for Intercept Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intercept Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
E10
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -11.48 -11.06 -10.46

Intercept Pharmaceuticals Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
E10 Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.34 -11.48 -10.67 -10.46 -10.63

Competitive Comparison

For the Biotechnology subindustry, Intercept Pharmaceuticals's E10, along with its competitors' market caps and E10 data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Intercept Pharmaceuticals E10 Distribution

For the Biotechnology industry and Healthcare sector, Intercept Pharmaceuticals's E10 distribution charts can be found below:

* The bar in red indicates where Intercept Pharmaceuticals's E10 falls in comparison to its industry or sector. The grey bar indicates the E10's extreme value range as defined by GuruFocus.



Intercept Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Intercept Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2023 (Change)*Current CPI (Mar. 2023)
=-0.77/127.3478*127.3478
=-0.770

Current CPI (Mar. 2023) = 127.3478.

Intercept Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201306 -0.790 98.518 -1.021
201309 -1.650 98.790 -2.127
201312 -0.610 98.326 -0.790
201403 -12.610 99.695 -16.108
201406 1.510 100.560 1.912
201409 -1.690 100.428 -2.143
201412 -1.630 99.070 -2.095
201503 -1.780 99.621 -2.275
201506 -1.990 100.684 -2.517
201509 -2.100 100.392 -2.664
201512 -3.620 99.792 -4.620
201603 -5.170 100.470 -6.553
201606 -3.140 101.688 -3.932
201609 -3.590 101.861 -4.488
201612 -4.840 101.863 -6.051
201703 -3.610 102.862 -4.469
201706 -3.460 103.349 -4.263
201709 -2.890 104.136 -3.534
201712 -4.430 104.011 -5.424
201803 -3.220 105.290 -3.895
201806 -2.580 106.317 -3.090
201809 -2.180 106.507 -2.607
201812 -2.970 105.998 -3.568
201903 -3.030 107.251 -3.598
201906 -2.280 108.070 -2.687
201909 -2.590 108.329 -3.045
201912 -2.990 108.420 -3.512
202003 -2.860 108.902 -3.344
202006 -1.920 108.767 -2.248
202009 -2.010 109.815 -2.331
202012 -1.580 109.897 -1.831
202103 -1.220 111.754 -1.390
202106 -0.330 114.631 -0.367
202109 -0.110 115.734 -0.121
202112 -1.230 117.630 -1.332
202203 -0.580 121.301 -0.609
202206 -0.250 125.017 -0.255
202209 7.800 125.227 7.932
202212 -0.500 125.222 -0.508
202303 -0.770 127.348 -0.770

Add all the adjusted EPS together and divide 10 will get our e10.


Intercept Pharmaceuticals  (NAS:ICPT) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Intercept Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Intercept Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Intercept Pharmaceuticals (NAS:ICPT) Business Description

Intercept Pharmaceuticals logo
Traded in Other Exchanges
Address
10 Hudson Yards, 37th Floor, New York, NY, USA, 10001
Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
Executives
Andrew Saik officer: EVP & Chief Financial Officer 640 LEE ROAD, CHESTERBROOK PA 19087
M Michelle Berrey officer: President, R&D and CMO 303A COLLEGE ROAD EAST, PRINCETON NJ 08450
Dagmar Rosa-bjorkeson director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Rocco Venezia officer: Chief Accounting Officer C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FLOOR, NEW YORK NY 10001
Lisa Defrancesco officer: SVP, IR & Corp. Affairs C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, FLOOR 37, NEW YORK NY 10001
Linda M Richardson officer: EVP & Chief Commercial Officer 2505 MERIDIAN PKWY, SUITE 340, C/O CHIMERIX, INC., DURHAM NC 27713
Jared Freedberg officer: General Counsel and Secretary 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Bryan Ball officer: Chief Quality Officer 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Paolo Fundaro director, 10 percent owner C/O GENEXTRA S.P.A.,, VIA G. DE GRASSI, 11, MILAN L6 20123
Keith Michael Gottesdiener director 900 FIFTH AVENUE, #8C, NEW YORK NY 10021
Luca Benatti director C/O INTERCEPT PHARMACEUTICALS, INC., 450 WEST 15TH STREET, SUITE 505, NEW YORK NY 10011
Daniel G Welch director 4611 UNIVERSITY DR, 4 UNIVERSITY PLACE, DURHAM NC 27707
Daniel Bradbury director BIOBRIT, LLC, 2223 AVENIDA DE LA PLAYA, SUITE 108, LA JOLLA CA 92037
Nancy Miller-rich director C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FL, NEW YORK NY 10001
Gino Santini director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451

Intercept Pharmaceuticals (NAS:ICPT) Headlines

Other Sources